1 / 25

Add-On Therapy to Insulin in T1DM Management

Explore the need for adjunct therapies in T1DM management and discover the potential of SGLT inhibitors. Learn about clinical trials, patient experiences, and strategies for managing DKA risks. Understand the CV benefits and other considerations for implementing these therapies.

kasper-blair
Download Presentation

Add-On Therapy to Insulin in T1DM Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Add-On Therapy to Insulin in T1DM Management

  2. Program Overview

  3. Why Adjunct Therapy is Needed in T1DM

  4. Adjunct Therapies: Pramlintide

  5. Adjunct Therapies: Metformin

  6. Adjunct Therapies: Newer Agents

  7. T2DM Therapies for T1DM: SGLT Inhibitors

  8. SGLT1/2 Inhibitors

  9. Clinical Trials With SGLT Inhibitors for T1DM

  10. Clinical Trials With SGLT Inhibitors for T1DM (cont)

  11. EASE 2&3 Subgroup Analysis - DKA

  12. Patient Experience of SGLT Adjunct Therapy

  13. Patient Experience of SGLT Adjunct Therapy (Cont)

  14. DKA Risk With SGLT Inhibitors

  15. Managing the DKA Risk

  16. Managing the DKA Risk (cont)

  17. Managing the DKA Risk (cont)

  18. STICH Protocol

  19. Educating ER Staff

  20. CV Benefits of SGLT Inhibitors

  21. Managing CV Risk in T1DM

  22. Other Considerations

  23. Conclusion

  24. Abbreviations

More Related